Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab Monotherapy or Combination Therapy in Richter's Transformation
NCT06043674Phase 2Recruiting
- Start
- Jan 2024
- Primary completion
- Jan 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of glofitamab in Richter's transformation (RT) (4 arms). Primary endpoint: Best Complete Response Rate at 36 weeks. Started Jan 2024; status: recruiting.
02
Drugs
glofitamab
03
Conditions
Richter's transformation (RT)
Beyond the preview
Go deeper on NCT06043674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06043674.